Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KIF18A | Q8NI77 | 2/20 | 0.36 |
| ▸ | GHSR | Q92847 | 1/20 | 0.34 |
| ▸ | SOS1 | Q07889 | 4/20 | 0.33 |
| ▸ | SCN1A | P35498 | 3/20 | 0.33 |
| ▸ | SCN8A | Q9UQD0 | 3/20 | 0.33 |
| ▸ | SCN9A | Q15858 | 2/20 | 0.32 |
| ▸ | WDR5 | P61964 | 1/20 | 0.32 |
| ▸ | KMO | O15229 | 2/20 | 0.31 |
| ▸ | RAF1 | P04049 | 2/20 | 0.31 |
| ▸ | BRAF | P15056 | 2/20 | 0.31 |
| ▸ | JAK1 | P23458 | 1/20 | 0.30 |
| ▸ | AXL | P30530 | 1/20 | 0.30 |
| ▸ | TRIM24 | O15164 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19925208 | 0.93 | KIF18A (0.36) | KIF18AGHSRSOS1SCN1ASCN8A | |
| SCHEMBL19925131 | 0.88 | GHSR (0.39) | GHSRSCN1ASCN8ASCN9AWDR5 | |
| SCHEMBL29464448 | 0.87 | KIF18A (0.36) | KIF18AGHSRSOS1SCN1ASCN8A | |
| SCHEMBL19925682 | 0.87 | KIF18A (0.36) | KIF18AGHSRSOS1SCN1ASCN8A | |
| SCHEMBL29464339 | 0.84 | KIF18A (0.34) | KIF18ASOS1RAF1BRAF | |
| SCHEMBL19951298 | 0.84 | KIF18A (0.34) | KIF18ASOS1RAF1BRAF | |
| SCHEMBL19968848 | 0.84 | KIF18A (0.37) | KIF18ASOS1SCN1ASCN8ASCN9A | |
| SCHEMBL29464520 | 0.82 | SCN9A (0.35) | KIF18AGHSRSCN1ASCN8ASCN9A | |
| SCHEMBL19927730 | 0.82 | SCN9A (0.35) | KIF18AGHSRSCN1ASCN8ASCN9A | |
| SCHEMBL29464385 | 0.82 | SOS1 (0.39) | KIF18ASOS1SCN9A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-109641873-B | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease | 诺华股份有限公司 | 2022-03-18 | — | — | CN | claimed |
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | claimed |
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | claimed |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | claimed |
| EP-3504194-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2019-07-03 | — | — | EP | claimed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | claimed |
| WO-2018042316-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2018-03-08 | — | — | WO | claimed |
| CN-109641873-B | N- (pyridin-2-yl) pyridine-sulfonamide derivatives and their use for the treatment of disease | 诺华股份有限公司 | 2022-03-18 | — | — | CN | disclosed |
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| EP-3504194-B1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2021-08-18 | — | — | EP | disclosed |
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2021-07-20 | — | — | US | disclosed |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | NOVARTIS AG (CH) | 2019-10-22 | — | — | US | disclosed |
| EP-3504194-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | Novartis AG (CH) | 2019-07-03 | — | — | EP | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | NOVARTIS AG (CH) | 2018-03-15 | — | — | US | disclosed |
| WO-2018042316-A1 | N-(PYRIDIN-2-YL)PYRIDINE-SULFONAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF DISEASE | NOVARTIS AG (CH) | 2018-03-08 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11066369-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | KIF18A 4084/4885GHSR 2080/4885SOS1 1308/4885 |
| US-20180072673-A1 | N-(pyridin-2-yl)pyridine-sulfonamide Derivatives and their Use in the Treatment of Disease | CFTR, P2RY1, P2RX5 | KIF18A 4084/4885GHSR 2080/4885SOS1 1308/4885 |
| US-10450273-B2 | N-(pyridin-2-yl)pyridine-sulfonamide derivatives and their use in the treatment of disease | CFTR, P2RY1, P2RX5 | KIF18A 4084/4885GHSR 2080/4885SOS1 1308/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.